Apriem Advisors Lowers stake in Pfizer (PFE)

Pfizer (PFE) : Apriem Advisors reduced its stake in Pfizer by 0.99% during the most recent quarter end. The investment management company now holds a total of 186,117 shares of Pfizer which is valued at $6,510,373 after selling 1,856 shares in Pfizer , the firm said in a disclosure report filed with the SEC on Aug 12, 2016.Pfizer makes up approximately 2.07% of Apriem Advisors’s portfolio.

Other Hedge Funds, Including , Texas Yale Capital Corp. reduced its stake in PFE by selling 1,685 shares or 4.54% in the most recent quarter. The Hedge Fund company now holds 35,419 shares of PFE which is valued at $1,238,957. Pfizer makes up approx 0.12% of Texas Yale Capital Corp.’s portfolio.Private Advisor Group boosted its stake in PFE in the latest quarter, The investment management firm added 45,360 additional shares and now holds a total of 390,426 shares of Pfizer which is valued at $13,637,580. Pfizer makes up approx 0.54% of Private Advisor Group’s portfolio.Kahn Brothers Group Inc De reduced its stake in PFE by selling 285,677 shares or 19.8% in the most recent quarter. The Hedge Fund company now holds 1,156,866 shares of PFE which is valued at $40,409,329. Pfizer makes up approx 7.45% of Kahn Brothers Group Inc De’s portfolio.Robshaw Julian Associates Inc reduced its stake in PFE by selling 16,614 shares or 14.43% in the most recent quarter. The Hedge Fund company now holds 98,528 shares of PFE which is valued at $3,491,832. Pfizer makes up approx 2.55% of Robshaw Julian Associates Inc’s portfolio.Hartford Investment Management Co reduced its stake in PFE by selling 46,285 shares or 2.92% in the most recent quarter. The Hedge Fund company now holds 1,536,725 shares of PFE which is valued at $56,459,277. Pfizer makes up approx 1.15% of Hartford Investment Management Co’s portfolio.

Pfizer opened for trading at $34.94 and hit $35.17 on the upside on Monday, eventually ending the session at $35.11, with a gain of 0.83% or 0.29 points. The heightened volatility saw the trading volume jump to 1,51,24,885 shares. Company has a market cap of $212,965 M.

On the company’s financial health, Pfizer reported $0.64 EPS for the quarter, beating the analyst consensus estimate by $ 0.02 according to the earnings call on Aug 2, 2016. Analyst had a consensus of $0.62. The company had revenue of $13147.00 million for the quarter, compared to analysts expectations of $13013.24 million. The company’s revenue was up 10.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.56 EPS.

Many Wall Street Analysts have commented on Pfizer. Shares were Reiterated by Jefferies on Jun 20, 2016 to “Buy” and Lowered the Price Target to $ 40 from a previous price target of $42 .

Pfizer Inc. is a global biopharmaceutical company. The Company is engaged in discovering developing and manufacturing of healthcare products. Its products include Lyrica the Prevnar family of products Enbrel Celebrex Lipitor Viagra Zyvox Sutent EpiPen Toviaz Tygacil Rapamune Xalkori Inlyta Norvasc BeneFIX Genotropin and Enbrel among others. It operates in three segments: Global Innovative Pharmaceutical segment (GIP) Global Vaccines Oncology and Consumer Healthcare segment (VOC) and Global Established Pharmaceutical segment (GEP). GIP is focused on developing registering and commercializing medications in therapeutic areas such as inflammation cardiovascular/metabolic neuroscience and pain rare diseases and women’s/men’s health. VOC focuses on the development and commercialization of vaccines and products for oncology and consumer healthcare. GEP includes its sterile injectable products and bio similar development portfolio. Its subsidiary is Hospira Inc.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *